Phase-II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephroma Journal Article

  


Authors: Scher, H. I.; Yagoda, A.; Ahmed, T.; Budman, D.; Sordillo, P.; Watson, R. C.
Article Title: Phase-II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephroma
Abstract: A phase-II trial of 4-demethoxydaunorubicin (4-DMDR) was performed in 21 patients with advanced renal cell carcinoma. The drug had demonstrated a broader spectrum of activity with less cardiotoxicity in preclinical evaluation than the parent compound daunorubicin. The starting dose was 12.5 mg/m2, with escalations to 15 and 17.5 mg/m2 in the absence of toxicity. Myelosuppression was the primary toxicity and cardiac toxicity was not seen in four patients who received four or more doses of DMDR. No responses were seen in 19 adequately treated patients, including 14 who had received no prior therapy. © 1985 Springer-Verlag.
Keywords: cancer chemotherapy; clinical article; aged; middle aged; fatigue; diarrhea; antineoplastic agents; anorexia; phase 2 clinical trial; nausea; vomiting; kidney carcinoma; kidney neoplasms; gastrointestinal toxicity; kidney; carcinoma, renal cell; cardiotoxicity; daunorubicin; idarubicin; drug therapy; alopecia; heart; adverse drug reaction; therapy; intravenous drug administration; bone marrow depression; drug evaluation; bisantrene; intoxication; humans; human; male; female; priority journal; blood and hemopoietic system
Journal Title: Cancer Chemotherapy and Pharmacology
Volume: 14
Issue: 1
ISSN: 0344-5704
Publisher: Springer  
Date Published: 1985-01-01
Start Page: 79
End Page: 80
Language: English
DOI: 10.1007/bf00552731
PUBMED: 3855289
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-0021925006&doi=10.1007%2fBF00552731&partnerID=40&md5=bba025e44a1d5445956a3993a61e3ba4
Notes: Article -- Export Date: 26 October 2021 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Howard Scher
    1130 Scher
  2. Alan Yagoda
    51 Yagoda
  3. Peter P. Sordillo
    20 Sordillo
  4. Robin Caird Watson
    25 Caird Watson
Related MSK Work